AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05287841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Batten batten graft
Description: The batten grafts are autologous grafts from the patients' own tissue, produced from nasal septal quadrangular cartilage. This will be obtained during the septoplasty portion of the procedure. The batten graft will be used to stabilize the internal nasal valve and prevent nasal valve collapse on inspiration.
Study NCT06268015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/kg IV every 2 weeks
Study NCT06688396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile 6L AI-EKG Screening
Description: Participants (probands) with DCM will invite their first-degree relatives to undergo DCM screening procedures.~Probands and first-degree relatives will complete a mobile 6L AI-EKG which will be transmitted to a mobile app and interpreted by the AI-EKG algorithm. Results will be shared electronically or verbally to the participant.~If available, the probands clinical 12L EKGs will be obtained if recorded within 30 days of their Kardia 6L recording.~All participating FDR will be encouraged to pursue cardiac screening per ACC/AHA recommendations. Study staff will obtain echocardiogram results up to 6 months of participant enrollment.
Study NCT06691256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HiDO-ALZ
Description: HiDO-ALZ platform, an AI-driven medication dispensing and observation system designed to improve adherence in individuals with dementia and diabetes.
Study NCT05287841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Septoplasty
Description: A portion of the quadrangular cartilage of the nasal septum is removed. This will be performed as a standard septoplasty.
Study NCT05287841 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Septoplasty
Description: A portion of the quadrangular cartilage of the nasal septum is removed. This will be performed as a standard septoplasty.
Study NCT06224855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DXC006
Description: Dose escalation period: DXC006 is administered intravenously every two weeks (Q2W) at the dose corresponding to the enrolled dose cohort.~Dose expansion period: DXC006 is administered intravenously Q2W at the corresponding dose.
Study NCT04821739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AGN1 LOEP SV Kit
Description: The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation.
Study NCT06696677 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT
Description: CT measurment of small bowel
Study NCT05287841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior Turbinate Reduction
Description: The bilateral inferior turbinates will be surgically ablated.
Study NCT05287841 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior Turbinate Reduction
Description: The bilateral inferior turbinates will be surgically ablated.
Study NCT04104815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Thickener
Description: Use to thicken liquids
Study NCT05242224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evolutionary Nutrition Package
Description: The evolutionary nutrition package includes two key components: 1) one full meal per day from the evolutionary nutrition (EN) plate; 2) targeted messaging for high quality nutrition and removal of ultra-processed foods from the diet. The EN plate includes five food groups identified from the literature on evolutionary diets: animal source foods (ASF); berries and other fruits; tubers; vegetables, herbs and spices; and nuts and other legumes.
Study NCT05540561 — intervention group
Intervention type: OTHER
Intervention: blood collection
Description: Biological analyses in the framework of care with conservation of blood samples
Study NCT04644237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan 100 mg will be provided as a sterile lyophilized powder and reconstituted with 5 mL water for injection (final concentration 20 mg/mL \[ie, 100 mg/5 mL\]). The study drug will be administered as an intravenous (IV) infusion over 30 to 90 min Q3W ± 2 days. The initial dose of study drug will be infused for 90 ± 10 min.
Study NCT05664958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane (ESP) Block
Description: ESP Block with liposomal bupivacaine and immediate release bupivacaine
Study NCT05664958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine liposome injectable suspension
Description: 133 mg liposomal bupivacaine per side.
Study NCT05664958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: 20 ml bupivacaine 0.25% per side.
Study NCT06696677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measuring the small instestine length using pre-marked laparoscopic graspers
Description: Intra-operatively, the surgeon will assess the length of the small intestine using a 5-cm marked laparoscopic graspers to accurately assess the whole small intestine length.
Study NCT05807139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone and its matched placebo will be encapsulated into hard gelatin capsules, in same color, size and taste, to allow blinding.~Participants will receive 2x50 mg/day, 2x100 mg, and 2x200 mg/day in three sessions (Stages); these Visits always occur in ascending order of dosage. In the remaining session, participants receive the placebo.~Spironolactone is approved by the FDA, commercially available, and used in clinical practice for the treatment of hypertension, NYHA Class III-IV heart failure, edema in cirrhotic patients, and primary hyperaldosteronism. Comprehensive information about spironolactone, including its pharmacological properties, are provided in the Prescribing Information.
Study NCT05743556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HILT laserotherapy
Description: application of high intensive laser therapy on cervical muscles
Study NCT05743556 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRT therapy
Description: application of radiofrekvention therapy on cervical muscles
Study NCT06225375 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Restorelle® Flat Mesh
Description: Pelvic organ prolapse repair using Restorelle® Flat Mesh
Study NCT05195957 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic tranversus abdominis release operation
Description: Mini-invasive robotic-assisted TAR using either DaVinci Xi or Si systems and 6 laparoscopic ports.
Study NCT05195957 — intervention group
Intervention type: PROCEDURE
Intervention: Open transversus abdominis release operation
Description: Original open TAR using midline incision.
Study NCT06601517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Single dose; Administered orally
Study NCT06601517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Single dose; Administered orally
Study NCT06601517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Single dose; Administered orally
Study NCT06601517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single dose; Administered orally
Study NCT06601517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1002
Description: Administered orally
Study NCT06605365 — intervention group
Intervention type: DEVICE
Intervention: CX-HA and CS
Description: Sterile Isotonic ophthalmic solution
Study NCT06661096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TMJ arthroscopy
Description: level I and level II TMJ arthroscopy
Study NCT06659328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Structured Walking Intervention for Children with Autism Spectrum Disorder
Description: Participants: Thirty children with ASD will participate in the walking sessions.~Conditions: Each child will walk under three different speed conditions:~Normal Speed: 120 beats per minute (bpm) Slow Speed: 100 bpm Fast Speed: 140 bpm~Social Interaction: Each child will walk with two different types of adult companions:~Familiar Adult: A caregiver or individual known to the child. Unfamiliar Adult: An adult not known to the child. Procedure: The walking distance will be 10 meters. The adult will wear a metronome in an earbud to ensure that they maintain the prescribed walking speed, which the child will be instructed to follow. Each child will experience all combinations of walking speeds and social interactions, allowing for a comprehensive assessment of how these factors influence gait parameters.~Gait Parameters: The following parameters will be recorded during each walking session using video analysis software (Kinovea©):~Stride length Step time Cadence Velocity Joint amplitudes
Study NCT04762433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kegel Exercise Pregnancy Training - app
Description: KEPT-app is designed to educate pregnant women on PFMT via the step-by-step training with the capability element to improve their confidence and skills (beginner, intermediate and advance skills). Pregnant women are encouraged to continue adopt the PFMT throughout pregnancy until postpartum period.~The details of the mHealth app content was developed based on the need assessment gathered from the cross-sectional study (Jaffar et al., 2020). It was conducted to identify the need of PFMT by looking at the prevalence of the UI among pregnant women and to understand their knowledge, attitude, and practices towards PFMT.
Study NCT05795231 — intervention group
Intervention type: DEVICE
Intervention: Macintosh Laryngoscope Vs Video Laryngoscope
Description: Evaluate incidence of first trial success and complications
Study NCT06599255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-guided RSB and TAPB by one-puncture technique.
Description: The probe will be positioned transversely in the midline of the abdomen, between the xiphoid process and the umbilicus, revealing the linea alba. It was then moved outward along the costal margin, demonstrating the rectus abdominis overlapping the transverse abdominis. A 22-gauge, 120-mm ultrasound-visible block needle will be inserted from the inner side . Under direct vision, we will reach the posterior rectus abdominis sheath and pierced the anterior layer of the posterior sheath. Saline was injected to adjust its position. After that, 15 mL of 0.25% bupivacaine will be administered (aspiration was performed for every 5 mL injection), and we will observe the local anesthetic spreading inward . Then, the needle will break through the posterior layer of the tendon, and saline will be injected to confirm the needle's placement in the transversus abdominis plane. After confirming the tip placement, 15 mL of 0.25% bupivacaine will be slowly injected. The needle tip will be advanced al
Study NCT06599255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: multipont
Description: , the probe will be moved outward along the costal margin until the external oblique muscle, internal oblique muscle, and transverse abdominis muscle will be visible \[9\]. The needle will be inserted in-plane until the tip was positioned in the plane between the internal oblique muscle and the transverse abdominis muscle. Then, 15 mL of 0.25% bupivacaine will be injected . The contralateral nerve block will be performed using the same method and volume of anesthetic solution.~For the RSB, the same technique will be done as one puncture technique. Then, 15 mL of 0.25% bupivacaine will be injected . The contralateral nerve block will be performed using the same method and volume of anesthetic solution.
Study NCT06701331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets taken orally once a day (Or equivalent oral solution taken two times a day)
Study NCT06701331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Tablets taken orally once a day (Or equivalent oral solution taken two times a day)
Study NCT06701331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablets taken orally once a day (Or equivalent oral solution taken two times a day)
Study NCT06627192 — intervention group
Intervention type: PROCEDURE
Intervention: NSPT, clinical and biochemical assesment
Description: Biochemical assessment using ELISA kit for Endcan and TNF alpha GCF sample
Study NCT06627231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-56286
Description: Oral capsule
Study NCT06627231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TEV-56286
Description: Oral capsule
Study NCT06634043 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally Advanced Tunel + ADM (Novomatrix®)
Description: ADM (Novomatrix®) will be used alone
Study NCT06634043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally Advanced Tunel + ADM (Novomatrix®) + L-PRF
Description: ADM in combination with L-Prf will be applied
Study NCT06634381 — intervention group
Intervention type: BEHAVIORAL
Intervention: CRF Visual Aid
Description: After all qualitative interviews and associated quantitative data analysis are complete, the visual aid will be created to illustrate, through a type of Venn Diagram, how the data are related.
Study NCT06633445 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A injection in lateral pterygoid muscle
Description: * Needle insertion guide will be placed on upper teeth.~* Needle will be inserted from needle insertion sleeve and 25-30 units of botulinum toxin type A will be injected.~* Aspiration will be done before injection, and then, the patient will be asked to manipulate the mandible to activate the lateral pterygoid muscle.
Study NCT06633445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: botox injection in lateral pterygoid muscle
Description: * A 27- gauge needle electrode will be inserted lateral to the maxillary tuberosity, just above the maxillary molars to inject 25-30 units of botulinum toxin type A under electromyographic guidance.~* Aspiration will be done before injection, and then the patient will be asked to manipulate the mandible to activate the lateral pterygoid muscle.~* The intramuscular injection will be confirmed when the electromyographic device produces a distinct loud sound.
Study NCT06619717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: Three treatments with hyperbaric oxygen therapy. The exact parameters of each dive will be left to individual clinicians. Commonly used treatments would be:~Weaver protocol, or similar (i.e. 100% oxygen at 3 atmospheres for 90 minutes with two 10-minute air breaks every 30 minutes. Repeat this every 8 hours until 3 treatments are complete.)
Study NCT06619717 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: Single treatment with hyperbaric oxygen. Exact parameters left to treating physician but commonly: 100% oxygen at 2.8 atmospheres for 30 minutes followed by a 10-minute air break, then 100% oxygen at 2 atmospheres for 60 minutes with one 10-minute air break after 30 minutes
Study NCT04805814 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CMR results disclosed
Description: The results of the CMR are disclosed, and used to guide management
Study NCT04805814 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: CMR performed but results not disclosed
Description: The results of the CMR are not disclosed, and management is angiography-guided
Study NCT06132048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MuCopilot mobile application
Description: MuCopilot is a software as medical device with three digital tests, to measure patient's with CF, lung function, global exercise capacity and a questionnaire to address CF symptoms and impacts on some aspects of patient's life
Study NCT06137157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR12-351
Description: Topical ointment containing ATR12-351, a LEKTI-secreting strain of S. epidermidis
Study NCT06049355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo Exercise Together exercise program, a supervised group exercise program delivered online, using a live remote format
Study NCT06049355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06049355 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06606379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I1 (Intervention)
Description: Resin ring (DR- Resin ring, Egypt)
Study NCT06606379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I2 (Intervention)
Description: Elliot separator (Pfingst \& Co, South Plainfield, NJ, USA)
Study NCT06606379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I3 (Intervention)
Description: Stainless Steel Metal ring (TOR VM ring, Moscow, Russia)
Study NCT06606379 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C (comparator)
Description: Nickel titanium 3D-fusion ring (Garrison, USA)
Study NCT06608758 — intervention group
Intervention type: BEHAVIORAL
Intervention: Electonic health record prompts with education
Description: 1). A baseline audit will be conducted of uses of Current Procedural Technology (CPT) Evaluation and Management (E/M) codes and evaluate for differences in complexity of CPT E/M code use for patients with disabilities (PWD) aged 3-89 years old with specific disabilities versus patients aged 3-89 without the specific disabilities.~Using analyses of data, chart reviews, staff interviews and mock tracers, a frame of themes underlying CPT code differences will be co-produced to develop algorithms to identify patients with the specified disabilities at risk. Case studies for education on DO, and EHR prompts, alerts, and decision supports related to the algorithms will be co-produced along with education on the EHR materials. Evaluate for change in use of CPT E/M among PWD after implementation of algorithms and EHR prompts, alerts and decision support will be conducted post-intervention.
Study NCT06608758 — intervention group
Intervention type: OTHER
Intervention: Standard of care
Description: Patients without disabilities will receive standard care related to electronic health record prompts, alerts, and decision supports.
Study NCT06659068 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seluang fish oil (Rasbora argyrotaenia) and synbiotic
Description: The patients received seluang fish oil (Rasbora argyrotaenia) and synbiotics (containing Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, Bifidobacterium bifidum R0071 20% and frukto-oligosaccharide 80 mg) supplementation
Study NCT06659068 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received placebo capsules
Study NCT04322305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin will be provided in 75 and 100 mg capsules twice daily for a maximum dose of 600 mg/day or the maximum tolerated dose over the 8 week medication phase and followed by a one week taper.
Study NCT04322305 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be provided twice daily over 8 weeks and one week taper..
Study NCT05434065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg
Description: Using celecoxib (200 mg/day) for 21 days starting within 6 hours after onset of ICH
Study NCT06607614 — intervention group
Intervention type: OTHER
Intervention: Colorectal Cancer Screening Fecal Immunochemical Test
Description: Fecal Immunochemical Test
Study NCT06606509 — intervention group
Intervention type: DEVICE
Intervention: Continuous Glucose Monitoring System (GX-01S)
Description: Patients with Type 1 Diabetes Mellitus (T1DM) will receive Continuous Glucose Monitoring System (GX-01S) for seven days.
Study NCT06598228 — intervention group
Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: no intervention
Study NCT04505553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture Therapy
Description: Undergo acupuncture
Study NCT04505553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure Therapy
Description: Undergo acupressure
Study NCT04505553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Cryotherapy
Description: Undergo oral cryotherapy
Study NCT04505553 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Cryotherapy
Description: Undergo oral cryotherapy
Study NCT04505553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04505553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04505553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04505553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05827549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blincyto
Description: Vincristine 1.5mg/m2, L-asparaginase 6,000 IU/m2 Idarubicin 10mg/m2 will be administered for induction therapy. Ifosfamide 1.8g/m2 Etoposide 100mg/m2 will be administered for consolidation therapy, then patients will be sorted into groups depend on their potential risk and Blinatumomab IV will be administered over 28 days. Intensification course will be administered 4 times repeated. 1. etoposide 100mg/m2 Ifosfamide 3.4g/m2 with MESNA / 2.oral 6-mercaptopurine 50mg/m2, methotrexate 25mg/m2 / 3.Ara-C 1.0g/m2, Idarubicin 5mg/m2 / 4.vincristine 2mg/m2 are the courses for repetition.